Leukeran (Chlorambucil)

Chlorambucil belongs to the nitrogen‑mustard class of alkylating agents. It binds to DNA bases and creates cross‑links that block DNA replication and transcription. This damage triggers cell‑cycle arrest and apoptosis, especially in rapidly dividing cancer cells.

The specific dose of Leukeran is individualized by the treating physician based on the patient’s diagnosis, disease stage, body surface area, and laboratory parameters. Dosing is adjusted for renal or hepatic function and monitored through regular blood tests.

Safety data for chlorambucil in pregnancy and lactation are limited. The drug is generally avoided in pregnant or nursing women because of potential fetal toxicity and excretion in breast milk. Use only if the potential benefit justifies the risk.

To request Leukeran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Leukeran is an oral alkylating agent, whereas alternatives such as cyclophosphamide are also alkylators but often administered intravenously. Chlorambucil has a longer half‑life and may be preferred for oral convenience, but both share similar myelosuppressive profiles and require careful monitoring.

Leukeran tablets should be stored at ambient temperature, below 25 °C, in their original container to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid environments such as bathrooms.

Leukeran is taken orally as a tablet with a full glass of water, usually on an empty stomach unless instructed otherwise by the prescriber. The exact schedule (daily, weekly, or cyclic) is determined by the treating oncologist.

The most serious risks include severe neutropenia leading to infection, hemorrhagic cystitis causing blood in the urine, and the rare possibility of secondary malignancies. Patients should report fever, persistent bleeding, or unusual urinary symptoms to their healthcare provider promptly.

Leukeran is contraindicated in patients with known hypersensitivity to chlorambucil or other nitrogen‑mustard agents, in those with severe bone‑marrow failure, and in individuals receiving live vaccines. Caution is also advised for patients with significant renal or hepatic impairment.